MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Approximately 25% of melanoma patients with locoregional metastases are nonresponsive to new molecular target therapy and immunotherapy. When metastases are located in the pelvis, melphalan hypoxic perfusion can be an optional treatment. Because methylation of MGMT promoter increases the efficacy of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Melanoma Res
Hauptverfasser: Guadagni, Stefano, Fiorentini, Giammaria, Clementi, Marco, Palumbo, Giancarlo, Masedu, Francesco, Deraco, Marcello, De Manzoni, Giovanni, Chiominto, Alessandro, Valenti, Marco, Pellegrini, Cristina
Format: Artigo
Sprache:Inglês
Veröffentlicht: Lippincott Williams & Wilkins 2017
Schlagworte:
ORIGINAL ARTICLES: Translational research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5592983/
https://ncbi.nlm.nih.gov/pubmed/28486243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000367
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge